Switch theme
Sign up to access all valuation multiples
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
2020
42
LTM Revenue $2.2M
LTM EBITDA -$65.4M
$432M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
LENZ Therapeutics has a last 12-month revenue of $2.2M and a last 12-month EBITDA of -$65.4M.
In the most recent fiscal year, LENZ Therapeutics achieved revenue of n/a and an EBITDA of -$58.6M.
LENZ Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LENZ Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$72.4M | -$58.6M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$10.8M | -$70.0M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, LENZ Therapeutics's stock price is $23.
LENZ Therapeutics has current market cap of $640M, and EV of $432M.
See LENZ Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $432M | $640M | XXX | XXX | XXX | XXX | $-2.53 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, LENZ Therapeutics has market cap of $640M and EV of $432M.
LENZ Therapeutics's trades at 198.7x LTM EV/Revenue multiple, and -6.6x LTM EBITDA.
Analysts estimate LENZ Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for LENZ Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $432M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -7.4x | XXX | XXX | XXX |
| P/E | -12.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -7.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLENZ Therapeutics's NTM/LTM revenue growth is 798%
LENZ Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.4M for the same period.
Over next 12 months, LENZ Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate LENZ Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for LENZ Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -19% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LENZ Therapeutics acquired XXX companies to date.
Last acquisition by LENZ Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . LENZ Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was LENZ Therapeutics founded? | LENZ Therapeutics was founded in 2020. |
| Where is LENZ Therapeutics headquartered? | LENZ Therapeutics is headquartered in United States of America. |
| How many employees does LENZ Therapeutics have? | As of today, LENZ Therapeutics has 42 employees. |
| Who is the CEO of LENZ Therapeutics? | LENZ Therapeutics's CEO is Mr. Evert B. Schimmelpennink. |
| Is LENZ Therapeutics publicy listed? | Yes, LENZ Therapeutics is a public company listed on NAS. |
| What is the stock symbol of LENZ Therapeutics? | LENZ Therapeutics trades under LENZ ticker. |
| When did LENZ Therapeutics go public? | LENZ Therapeutics went public in 2024. |
| Who are competitors of LENZ Therapeutics? | Similar companies to LENZ Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of LENZ Therapeutics? | LENZ Therapeutics's current market cap is $640M |
| What is the current revenue of LENZ Therapeutics? | LENZ Therapeutics's last 12-month revenue is $2.2M. |
| What is the current EBITDA of LENZ Therapeutics? | LENZ Therapeutics's last 12-month EBITDA is -$65.4M. |
| What is the current EV/Revenue multiple of LENZ Therapeutics? | Current revenue multiple of LENZ Therapeutics is 198.7x. |
| What is the current EV/EBITDA multiple of LENZ Therapeutics? | Current EBITDA multiple of LENZ Therapeutics is -6.6x. |
| Is LENZ Therapeutics profitable? | Yes, LENZ Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
